Cargando…
Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer derived from the malignant transformation of T-cell progenitors. Outcomes remain poor for T-ALL patients who have either primary resistance to standard-of-care chemotherapy or disease relapse. Notably, there are currentl...
Autores principales: | Gao, Jie, Van Meter, Michael, Hernandez Lopez, Susana, Chen, Guoying, Huang, Ying, Ren, Shumei, Zhao, Qi, Rojas, Jose, Gurer, Cagan, Thurston, Gavin, Kuhnert, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765191/ https://www.ncbi.nlm.nih.gov/pubmed/31399482 http://dx.doi.org/10.1242/dmm.040931 |
Ejemplares similares
-
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
por: Kuhnert, Frank, et al.
Publicado: (2011) -
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022) -
Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression
por: Tsaouli, Georgia, et al.
Publicado: (2019) -
The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia
por: Choi, Sung Hee, et al.
Publicado: (2017) -
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)